Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Topic
Recurrence Surveillance
Topic
Recurrence Surveillance
Blood Test Flags Melanoma Recurrence 70.5 Days Before Clinical Detection
A blood test detected melanoma recurrence a median of 70.5 days before clinical exam, per a Stock Titan report, though analyte, c…